AstraZeneca

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, focused on developing innovative treatments for prevalent retinal diseases. Founded by experienced leaders in ophthalmology, the company aims to address significant unmet needs by creating therapies that ease the burden on patients and caregivers while improving treatment outcomes. The company's lead product, TH103, is a fully humanized recombinant fusion protein designed for intravitreal delivery, demonstrating potential as a best-in-class anti-VEGF agent. With an experienced management team and support from veteran investors, Kalaris is currently evaluating TH103 in a Phase 1 clinical trial for neovascular age-related macular degeneration, with plans to expand its application to other neovascular and exudative retinal diseases. Generated from the website

Founded in 1987, Gilead Sciences is one of the leaders in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA and RNA in the United States. The company discovers, develops and commercializes medications to advance the care of patients suffering from life-threatening diseases. Headquartered in Foster City, Calif., it serves North America, Europe and Australia and employs a staff of more than 3,400 individuals. Gilead Sciences areas of focus include antivirals, such as HIV/AIDS and chronic hepatitis, as well as cardiovascular conditions, including pulmonary arterial hypertension and resistant hypertension. The company also conducts studies on various respiratory diseases, such as influenza and cystic fibrosis.